This brief examines efforts in 11 states to fill in funding gaps created by the 2025 federal budget reconciliation law, which prohibits federal Medicaid funding for reproductive-health care services provided by Planned Parenthood and other organizations that also provide abortion care.
This policy watch describes recent Trump administration changes to Medicaid vaccine reporting requirements and explores what the end of state reporting requirements may mean for how the U.S. tracks childhood vaccinations rates.
[Sponsored] A white paper from Imagine360 explores emerging trends that are reshaping the healthcare landscape and influencing how employers will make health plan decisions in the future. The post 5 Healthcare Affordability Trends to Track in 2026 and Beyond appeared first on MedCity News.
SACRAMENTO, Calif. — Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year. Health officials are recommending diet and exercise as alternatives to heavily advertised weight loss drugs like Wegovy and Zepbound, advice experts say is unrealistic. “Of course he tried eating well…
NEW ORLEANS — From the outside, the abandoned Family Dollar store in the Lower 9th Ward looks intimidating. It’s covered in graffiti, with aluminum cans and trash dotting the parking lot. It sits on a street with other empty lots and decayed buildings — symbols of the lasting devastation this neighborhood, one of the city’s…
Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies…
Medicare Drug Price Negotiation aims to reduce the prices paid for high cost pharmaceuticals. Traditionally, biologic drug price reductions after loss of exclusivity (LOE) have occurred due to the introduction of biosimilar competitors. A recent paper by Beinfeld et al. 2025 examines whether Medicare Drug Price Negotiation enacted under the Inflation Reduction Act (IRA) is…
CMS has introduced the MAHA ELEVATE model to expand lifestyle medicine in Medicare, a move experts support but say will hinge on effective implementation. The post What Health Experts Are Saying About the MAHA ELEVATE Program appeared first on MedCity News.
Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk. The post Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs…
Passage of the bill in the Senate remains uncertain